-The Times of India The Centre on Thursday responded to the Supreme Court's concern over spiralling Prices of essential medicines and promised to make all-out efforts to put under strict price control regime all the 348 drugs included in the National List of Essential Medicines (NLEM), 2011. A bench comprising Justices G S Singhvi and S J Mukhopadhaya had, in the last hearing, expressed concern over the shrinking list of medicines under...
More »SEARCH RESULT
Rein in drug prices, SC tells govt
-The Telegraph The Supreme Court today asked the Centre to ensure that drug prices go down, not up, if and when a new price control policy comes into force. “Prices may go down but should not go up because of policy,” Justice S.J. Mukhopadhyay, sitting alongside senior judge G.S. Singhvi, said. “Bring it down, don’t escalate it in the name of policy,” the bench told additional solicitor-general Parag Tripathi, who was speaking...
More »New pharma policy to cap prices of 60% drugs by Namrata Nandakumar & CH Unnikrishnan
India’s new pharmaceutical policy seeks to bring at least 400 essential medicines—or 60% of the drugs sold in the country—under the government’s pricing control. The department of pharmaceuticals on Friday put out a draft policy, pending since 2005, after a committee prepared a list of essential medicines, laying down new rules governing drug pricing. Currently, the government controls the prices of only 34 essential medicines. The draft says the policy, to be finalized...
More »Medicines: For Saving Life or For Superprofits? by Bharat Dogra
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage. It may be pointed out here that as early as...
More »Affordable medicine
-The Business Standard It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries’ demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for...
More »